Wednesday, February 18, 2026 Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant ChemotherapyDetection of molecular residual disease using circulating tumor DNA (ctDNA) may enable postoperative risk stratification and guide adjuvant therapy. The researchers evaluated the prognostic value of a tissue-free, epigenomic ctDNA assay in patients with stage III colon cancer (CC) enrolled in a phase III adjuvant chemotherapy trial. Sinicrope FA, Segovia D, Sharma n, Alberts SR, Hardin A, Rich T, Shi Q. Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147) (ONLINE). Journal of Clinical Oncology 2026. https://ascopubs.org/doi/abs/10.1200/JCO-25-02086
